Human AB Serum and Thrombin-Activated Platelet-Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue

Stem Cells - Tập 25 Số 5 - Trang 1270-1278 - 2007
Asli Kocaoemer1, Susanne Kern1, Harald Klüter1, Karen Bieback1
1Institute of Transfusion Medicine and Immunology, German Red Cross Blood Service of Baden-Württemberg – Hessen, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany

Tóm tắt

Abstract MSCs are currently in focus regarding their clinical potential in cell therapy and tissue engineering. However, most isolation and expansion protocols for clinical-scale production of MSCs use fetal calf serum (FCS) as a supplement, which poses a potential risk for infections as well as immunological reactions. To find a suitable FCS substitute, we investigated the effects of pooled human AB serum (AB-HS) and thrombin-activated platelet-rich plasma (tPRP) on adipose tissue MSCs (AT-MSCs) with FCS as the standard control medium. AT-MSCs of 10 donors were cultured under three different conditions: (a) 10% FCS, (b) 10% AB-HS, and (c) 10% tPRP. Colony-forming units, cumulative population doubling rates, and differentiation capacity toward the adipogenic and osteogenic lineages were assessed, along with immunophenotype. We demonstrated that AB-HS and tPRP provide a significantly higher proliferative effect on AT-MSCs than does FCS. In the first six passages, AB-HS and tPRP MSCs exhibited a fold expansion of 66.6 ± 15.7 and 68.1 ± 6.7, respectively, compared with 24.4 ± 0.7 for FCS. Differentiation capacity was preserved throughout long-term culture. Immunophenotype was characteristic for MSCs and comparable for all culture conditions with the exception of a distinct CD45-/CD14-positive side population for AB-HS and tPRP that tended to diminish with prolonged culture. We showed that pooled human AB serum and thrombin-activated platelet-rich plasma are alternatives to FCS for AT-MSCs. These human sources are better characterized regarding potential infectious threats, while providing a higher proliferation rate and retaining differentiation capacity and mesenchymal stem cell marker expression throughout long-term culture. Disclosure of potential conflicts of interest is found at the end of this article.

Từ khóa


Tài liệu tham khảo

Caplan, 1991, Mesenchymal stem cells, J Orthop Res, 9, 641, 10.1002/jor.1100090504

Bieback, 2004, Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood, Stem Cells, 22, 625, 10.1634/stemcells.22-4-625

Kern, 2006, Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue, Stem Cells, 24, 1294, 10.1634/stemcells.2005-0342

Kassem, 2004, Mesenchymal stem cells: Cell biology and potential use in therapy, Basic Clin Pharmacol Toxicol, 95, 209, 10.1111/j.1742-7843.2004.pto950502.x

Pittenger, 1999, Multilineage potential of adult human mesenchymal stem cells, Science, 284, 143, 10.1126/science.284.5411.143

Lee, 2004, In vitro hepatic differentiation of human mesenchymal stem cells, Hepatology, 40, 1275, 10.1002/hep.20469

Munoz-Elias, 2003, Marrow stromal cells, mitosis, and neuronal differentiation: Stem cell and precursor functions, Stem Cells, 21, 437, 10.1634/stemcells.21-4-437

Chen, 2004, Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction, Am J Cardiol, 94, 92, 10.1016/j.amjcard.2004.03.034

Le Blanc, 2004, Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, 363, 1439, 10.1016/S0140-6736(04)16104-7

Koç, 2000, Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy, J Clin Oncol, 18, 307, 10.1200/JCO.2000.18.2.307

Spees, 2004, Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy, Mol Ther, 9, 747, 10.1016/j.ymthe.2004.02.012

1997, Medicinal and other products and human and animal transmissible spongiform encephalopathies: Memorandum from a WHO meeting, Bull World Health Organ, 75, 505

Selvaggi, 1997, Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions, Blood, 89, 776, 10.1182/blood.V89.3.776

Tuschong, 2002, Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy, Hum Gene Ther, 13, 1605, 10.1089/10430340260201699

Drach, 1977, Transfer and induction of delayed hypersensitivity to methylated bovine serum albumin in the absence of adjuvant, C R Acad Sci Hebd Seances Acad Sci D, 284, 2435

Stute, 2004, Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use, Exp Hematol, 32, 1212, 10.1016/j.exphem.2004.09.003

Doucet, 2005, Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications, J Cell Physiol, 205, 228, 10.1002/jcp.20391

Kilian, 2004, Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro, Eur J Med Res, 9, 337

Gruber, 2004, Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions, Platelets, 15, 29, 10.1080/09537100310001643999

Tamama, 2006, Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells, Stem Cells, 24, 686, 10.1634/stemcells.2005-0176

Kobayashi, 2005, Motility and growth of human bone-marrow mesenchymal stem cells during ex vivo expansion in autologous serum, J Bone Joint Surg Br, 87, 1426, 10.1302/0301-620X.87B10.16160

Shahdadfar, 2005, In vitro expansion of human mesenchymal stem cells: Choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability, Stem Cells, 23, 1357, 10.1634/stemcells.2005-0094

Anselme, 2002, In vitro control of human bone marrow stromal cells for bone tissue engineering, Tissue Eng, 8, 941, 10.1089/107632702320934047

Janetzko, 2004, Fully automated processing of buffy-coat-derived pooled platelet concentrates, Transfusion, 44, 1052, 10.1111/j.1537-2995.2004.03296.x

Gaarder, 1961, Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets, Nature, 192, 531, 10.1038/192531a0

Rand, 1996, Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: Direct measurement of percent release of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression, Am J Hematol, 52, 288, 10.1002/(SICI)1096-8652(199608)52:4<288::AID-AJH8>3.0.CO;2-O

Bang, 2005, Autologous mesenchymal stem cell transplantation in stroke patients, Ann Neurol, 57, 874, 10.1002/ana.20501

Mazzini, 2003, Stem cell therapy in amyotrophic lateral sclerosis: A methodological approach in humans, Amyotroph Lateral Scler Other Motor Neuron Disord, 4, 158, 10.1080/14660820310014653

Chen, 2004, Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction, Chin Med J, 117, 1443

Dimarakis, 2006, Cell culture medium composition and translational adult bone marrow-derived stem cell research, Stem Cells, 24, 1407, 10.1634/stemcells.2005-0577

Baksh, 2004, Adult mesenchymal stem cells: Characterization, differentiation, and application in cell and gene therapy, J Cell Mol Med, 8, 301, 10.1111/j.1582-4934.2004.tb00320.x

Yoshimura, 2006, Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates, J Cell Physiol, 208, 64, 10.1002/jcp.20636

Sotiropoulou, 2006, Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells, Stem Cells, 24, 462, 10.1634/stemcells.2004-0331

Ponta, 2003, CD44: From adhesion to signaling regulators, Nat Rev Mol Cell Biol, 4, 33, 10.1038/nrm1004

Gronthos, 1995, The growth factor requirements of STRO-1-positive human bone marrow stromal precursors under serum-deprived conditions in vitro, Blood, 85, 929, 10.1182/blood.V85.4.929.bloodjournal854929

Kuznetsov, 1997, Factors required for bone marrow stromal fibroblast colony formation in vitro, Br J Haematol, 97, 561, 10.1046/j.1365-2141.1997.902904.x

Foreman, 2006, Characterisation of serum-induced intracellular Ca2+ oscillations in primary bone marrow stromal cells, J Cell Physiol, 206, 664, 10.1002/jcp.20521

Sotiropoulou, 2006, Cell culture medium composition and translational adult bone marrow-derived stem cell research, Stem Cells, 24, 1409, 10.1634/stemcells.2005-0654

Yamaguchi, 2002, Bone marrow stromal cells prepared using AB serum and bFGF for hematopoietic stem cells expansion, Transfusion, 42, 921, 10.1046/j.1537-2995.2002.00149.x

Marx, 2004, Platelet-rich plasma: Evidence to support its use, J Oral Maxillofac Surg, 62, 489, 10.1016/j.joms.2003.12.003

Barry, 1999, Mechanisms of cellular activation by platelet microparticles, Thromb Haemost, 82, 794, 10.1055/s-0037-1615913

Gruber, 2002, Platelets stimulate proliferation of bone cells: Involvement of platelet-derived growth factor, microparticles and membranes, Clin Oral Implants Res, 13, 529, 10.1034/j.1600-0501.2002.130513.x

Senger, 1994, Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain, Mol Biol Cell, 5, 565, 10.1091/mbc.5.5.565

Santoso, 2003, Human platelet alloantigens, Transfus Apher Sci, 28, 227, 10.1016/S1473-0502(03)00040-5

Thông tin
Thông tin xuất bản

Stem Cells

Tập 25 Số 5

1270-1278

Thông tin tác giả